Compare FBYD & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | LUCD |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 207 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.8M | 190.8M |
| IPO Year | N/A | 2021 |
| Metric | FBYD | LUCD |
|---|---|---|
| Price | $15.61 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 103.4K | ★ 684.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | $268.88 | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $3.71 | $0.95 |
| 52 Week High | $29.02 | $1.70 |
| Indicator | FBYD | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 55.51 |
| Support Level | $10.27 | $1.01 |
| Resistance Level | $16.00 | $1.52 |
| Average True Range (ATR) | 1.83 | 0.08 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 79.32 | 59.81 |
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.